Ionis Pharmaceuticals: The Heartbreak Is Priced In (NASDAQ:IONS)

Ionis is rated a Buy with a valuation offering attractive upside despite reimbursement, competition, and execution risks. Read more on IONS stock here.

Read on WOBR AI →